CNTX-6970 / Centrexion Therap - LARVOL DELTA

The Early Phase Pain Investigation Clinical Network for Non-addictive Pain Therapeutics Trials. (IASP 2024) - "The first trial (A 24-week study to evaluate the safety and efficacy of CNTX-6970 in subjects with moderate to severe knee osteoarthritis pain) evaluates the safety and efficacy of a novel oral drug for treatment of patients with moderate to severe knee osteoarthritis pain and recently finished enrolling patients. The second funded trial (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants with Painful Diabetic Peripheral Neuropathy) is of a novel oral small molecule targeting PDPN being studied under the platform protocol, and is currently open to enrollment... EPPIC-Net welcomes applications for assets that target pain conditions lacking adequate treatment. Applications are accepted and reviewed on a rolling basis. Applicants provide clinical-grade asset for the trial and retain asset ownership and intellectual property rights."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Diabetic Neuropathy • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Peripheral Neuropathic Pain • Psychiatry • Rheumatology

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain. (clinicaltrials.gov) - P2 | N=77 | Completed | Sponsor: Maurizio Fava, MD | Active, not recruiting ➔ Completed

Trial completion • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain. (clinicaltrials.gov) - P2 | N=77 | Active, not recruiting | Sponsor: Maurizio Fava, MD | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain. (clinicaltrials.gov) - P2 | N=77 | Recruiting | Sponsor: Maurizio Fava, MD | N=50 ➔ 77 | Trial primary completion date: Sep 2023 ➔ Jul 2024

Enrollment change • Trial primary completion date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology